Grade B · 77/100
💰 Valuation at a glance
Yahoo FinancePrice ÷ EPS. Lower is cheaper vs earnings. Forward-earnings basis.
🎯 Fair-value estimate
Near fair valueCurrent $240.33 — vs fair value +0.6%
※ A theoretical estimate from an objective multiple model — not a price target or a buy/sell recommendation. Investment decisions and responsibility rest with the user.
📊 Price trend
Open in Multi-chart →Yahoo Finance🎯 7-metric analysis
Based on latest annual results
B77 pts
Value axes (P/E, P/B, EV) are growth- & profitability-adjusted — premium growth names aren’t pinned to zero. (Losses / negative equity stay 0.)
📈 Key metrics
Yahoo Finance🏢 Peer comparison
Health CareSide by side with the largest names in the same sector. Green beats the sector median.
| Stock | P/E | P/B | ROE | Dividend |
|---|---|---|---|---|
| ResMed|Current | 23.1× | 5.26× | 23.4% | 1.0% |
| Lilly (Eli) | 39.5× | 30.91× | 78.8% | 0.6% |
| Johnson & Johnson | 31.1× |
🏦 Dividend vs deposit rate
This stock's 1.02% dividend is -2.98%p lower than 1Y Treasury yield (4.00%)
⚠️ Unlike a deposit, a dividend comes with principal (price) risk. Even if the yield beats the rate, a falling price can still mean an overall loss. Treat dividend as just one reference metric.
As of: U.S. Treasury Par Yield (1Y) · 4.00% (2026-05)
📡 Technical signals
📊 Uptrend alignment (short-term bullish) · RSI 69 neutral
Above the moving averages means short-term bullish; below means bearish. RSI ≥ 70 is overbought and ≤ 30 is oversold.
🎮 What if you had bought?
If you'd bought ResMed| in the past, what would it be worth now? Play with the period and amount. (For reference · not a buy recommendation)
※ Simple close-price math, excluding fees, taxes and dividends. Past returns don’t guarantee future results.
📰 Related news
Source: Naver Finance (KR) · Yahoo Finance (US) · external article links
💼 Financial statements
Yahoo FinanceRecent annual
| Period | Revenue | Op. income | Net income | Op. margin |
|---|---|---|---|---|
| 2025 FY | $5.15B | $1.69B | $1.40B | 32.7% |
| 2024 FY | $4.69B | $1.38B | $1.02B | 29.5% |
| 2023 FY | $4.22B | $1.15B | $897.6M | 27.3% |
| 2022 FY | $3.58B | $1.00B | $779.4M | 28.0% |
Quarterly results (last 5 quarters)
📚 Metrics & scoringShow moreCollapse
🔎 Data sources & methodologyShow moreCollapse
Every score is auto-computed from the public data below. No manual adjustment.
| Item | Source | Method · update cadence |
|---|---|---|
| Price · volume · 52W | Yahoo Finance | Stored as-is · hourly intraday |
| Financials (revenue, profit, equity, debt) | Yahoo fundamentalsTimeSeries | Annual + quarterly reported · refreshed over ~1 week |
| Short-term (TTM) score | Computed (quarterly financials) | Sum of last 4 quarters + YoY momentum vs same quarter a year ago · daily |
| PER · PBR | Yahoo reported (US) | Yahoo priceToBook · trailingPE |
| Dividend yield | Yahoo Finance | Annual dividend ÷ price · 0% if none |
| ROE · operating margin · debt ratio |